IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY

STANLEY PLISZKA)	
)	C.A. No.:
Plaintiff,)	
		COMPLAINT
V.)	
)	JURY TRIAL DEMANDED
C.R. BARD, INC., and BARD DAVOL, INC.,)	
)	
Defendants.		

COMPLAINT AND JURY DEMAND

COMES NOW, Plaintiff, STANLEY PLISZCA (hereinafter "Plaintiff") by and through undersigned counsel, brings this Complaint for damages against Defendants and in support thereof states the following:

I. INTRODUCTION

1. This is a device tort action brought on behalf of the above-named Plaintiff arising out of the failure of Defendants' hernia mesh product, the Bard Ventralex Hernia Patch ("Bard Mesh"). As a result, Plaintiff Stanley Pliszka has suffered permanent injuries and significant pain and suffering, emotional distress, lost wages and earning capacity, and diminished quality of life. Plaintiff respectfully seeks all damages to which he may be legally entitled.

II. STATEMENT OF PARTIES

- 2. Plaintiff is, and was at all relevant times, a citizen and resident of Pennsylvania and the United States.
- 3. C.R. Bard, Inc. ("Bard") is incorporated and based in New Jersey. Bard is a multinational marketer, promoter, seller, producer, manufacturer, and developer of medical 00474791;V1 00416934;V1 1

devices. Bard controls the largest share of the hernia mesh market. It is the corporate parent/stockholder of Davol and participates in the manufacture and distribution of the Bard Mesh. Bard also manufactures and supplies Davol with material that forms part of the Bard Mesh.

- 4. Davol, Inc. ("Davol") is incorporated in Delaware and has its principal place of business in Rhode Island. Davol is a medical device company involved in the research, development, testing, manufacture, production, marketing, promotion and/or sale of medical devices, including Bard Mesh composed of polypropylene.
- 5. Bard was at all times relevant responsible for the actions of Davol, and exercised control over Davol's functions specific to the oversight of and compliance with applicable safety standards relating to and including Bard Mesh sold in the United States. In such capacity, Bard committed or allowed to be committed tortious and wrongful acts, including the violation of numerous safety standards relating to device manufacturing, quality assurance/control, and conformance with design and manufacturing specifications. Bard's misfeasance and malfeasance caused Plaintiff to suffer injury and damages.
- 6. Defendants are individually, jointly and severally liable to Plaintiff for damages suffered by Plaintiff arising from their design, manufacture, marketing, labeling, distribution, sale and placement of the defective Bard Mesh at issue in this suit. All acts were effectuated directly and indirectly through Defendant's respective agents, servants, employees and/or owners, acting within the course and scope of their representative agencies, services, employments and/or ownership.

7. Defendants are vicariously liable for the acts and/or omissions of their employees and/or agents, who were at all times relevant acting on Defendants' behalf and within the scope of their employment or agency with Defendants.

III. VENUE AND JURISDICTION

- 8. This Court has subject matter jurisdiction pursuant to 28 U.S.C. § 1332(a), based on complete diversity of citizenship between Plaintiff and all Defendants. The amount in controversy exceeds \$75,000.00.
- 9. Venue is proper in this Court pursuant to 28 U.S.C. §1332(a)-(c) by virtue of the facts that (a) a substantial part of the acts or omissions giving rise to Plaintiff's claims occurred in this District; (b) Defendants' product are sold to and consumed by individuals in the State of New Jersey; (c) Bard is incorporated and maintains its principal place of business in the State of New Jersey. Defendants are thus subject to personal jurisdiction in this action and made "residents" of this judicial District.
- 10. Defendants have conducted, and continue to conduct, substantial business in the State of New Jersey and in this District; distribute Bard Mesh in this District; receive substantial compensation and profits from sales of Bard Mesh in this District; and make material omissions and misrepresentations and breaches of warranties in this District, so as to subject them to personal jurisdiction in this District.
 - 11. Davol is registered to transact business in New Jersey.

FACTS COMMON TO ALL COUNTS

12. On or about November 4, 2009, Plaintiff Stanley Pliszka underwent an epigastric hernia repair by Dr. Robin Rosenberg at Jefferson Torresdale Hospital, in Philadelphia,

Pennsylvania. An Bard Ventralex Hernia Patch, Medium Circle with Strap, Ref. No. 0010302, Lot No. HUS10446 was implanted in Plaintiff during this repair.

- 13. Defendants manufactured, sold, and/or distributed the Bard Mesh to Plaintiff, through Plaintiff's doctors, to be used for treatment of hernia repair.
- 14. On or about August 04, 2016, Plaintiff Stanley Pliszka underwent removal of the defective Bard Mesh by Dr. Sanjiv Dewan at the Jeanes Hospital in Philadelphia, Pennsylvania.
 - 15. Plaintiff continues to suffer pain and permanent disfigurement and chronic pain.
- 16. The Ventralex patch is a bilayer construction of a self-expanding patch containing two layers of polypropylene mesh stitched with polytetrafluorethylene (PTFE) monofilament to an expanded polytetrafluoroethylene (ePTFE) sheet. The mesh component is described as containing a "fully absorbable" recoil ring using SorbaFlex Memory Technology, an absorbable polydioxanone (PDO) monofilament.
- 17. Despite Defendants' claims that this material is inert, a substantial body of scientific evidence shows that the mesh material is biologically incompatible with human tissue and promotes an immune response in a large subset of the population receiving the product. This immune response promotes degradation and contracture of the polypropylene mesh, as well as the surrounding tissue, and can contribute to the formation of severe adverse reactions to the mesh.
- 18. Upon information and belief, Defendants' numerous suppliers of various forms of polypropylene cautioned all users in their United States Material Safety Data Sheet that the polypropylene was not to be used for medical applications involving permanent implantation in the human body or permanent contact with internal body fluids or tissues.

- 19. Defendants failed to warn or notify doctors, regulatory agencies, and consumers of the severe and life-threatening risks associated with polypropylene.
- 20. Defendants were responsible for the research, design, development, testing, manufacture, production, marketing, promotion, distribution and sale of Bard Mesh, including providing the warnings and instructions concerning the product.
- 21. Among the intended purposes for which Defendants designed, manufactured and sold the Bard Mesh is use by surgeons for hernia repair surgeries. That is the purpose for which the Bard Mesh was implanted in Plaintiff.
- 22. Defendants represented to Plaintiff and Plaintiff's physicians that the Bard Mesh was safe and an effective product for hernia repair.

ESTOPPEL AND TOLLING OF STATUTE OF LIMITATIONS

- 23. Plaintiff incorporates the allegations in all prior paragraphs.
- 24. Plaintiff asserts all applicable state statutory and common law rights and theories related to the tolling or extension of any applicable statute of limitations, including equitable tolling, class action tolling, delayed discovery, discovery rule, and fraudulent concealment.
- 25. Plaintiff pleads that the discovery rule should be applied to toll the running of the statute until Plaintiff knew, or through the exercise of reasonable care and diligence should have known, of facts indicating his injury, the cause of the injury, and the tortious nature of the wrongdoing that caused the injury.
- 26. Despite diligent investigation by Plaintiff into the cause of his injuries, including consultations with Plaintiff's medical providers, the nature of the injuries and damages, and their relationship to the Bard Mesh was not discovered, and through reasonable care and diligence could not have been discovered, until a date within the applicable statute of limitations for filing

Plaintiff's claims. Therefore, under appropriate application of the discovery rule, the action was filed well within the applicable statutory limitations period.

27. The running of the statute of limitations is tolled due to equitable tolling. Defendants are estopped from asserting a limitations defense due to their fraudulent concealment, through misrepresentations and omissions, from Plaintiff and Plaintiff's physicians of the true risks associated with the Bard Mesh. As a result of Defendants' fraudulent concealment, Plaintiff and his physicians were unaware, and could not have known or have learned through reasonable diligence, that Plaintiff had been exposed to the risks alleged in this Complaint, and that those risks were the direct and proximate result of Defendants' wrongful acts and omissions. As a result of Defendants' actions, Plaintiff and physicians were unaware, and could not reasonably have known or have learned through reasonable diligence, that they had been exposed to the risks alleged herein and that those risks were the direct and proximate result of Defendants' acts and omissions.

CAUSES OF ACTION - THEORIES OF RECOVERY COUNT I: STRICT LIABILITY - MANUFACTURING DEFECT

- 28. Plaintiff repeats, reiterates and realleges each and every allegation of this Complaint with the same force and effect as if more fully set forth herein.
- 29. Defendants expected and intended the Bard Mesh to reach users such as Plaintiff in the condition in which the product was sold.
- 30. The implantation of Bard Mesh in Plaintiff's body was medically reasonable, and was a type of use that Defendants intended and foresaw when they designed, manufactured and sold the product.

- 31. The Bard Mesh was defectively manufactured when it was implanted in Plaintiff's body.
- 32. Defendants' poor quality control and general non-compliance resulted in the nonconformance of the Bard Mesh implanted in Plaintiff. The implanted Bard Mesh did not conform to Defendants' intended manufacturing and design specifications.
- 33. Upon information and belief, Defendants utilized substandard and adulterated polypropylene in the Bard Mesh, which deviated from Defendants' material and supply specifications.
- 34. As a direct and proximate result of Defendants' defective manufacture of the Bard Mesh, Plaintiff suffered injuries and damages as summarized in this Complaint.

COUNT II: STRICT LIABILITY – DESIGN DEFECT

- 35. Plaintiff incorporates by reference the allegations in all prior paragraphs.
- 36. Defendants' Bard Mesh was defectively designed and/or manufactured and was not reasonably safe for its intended use in hernia repair. The risks of the design outweighed any potential benefits associated with the design. As a result of the defective design and/or manufacture of the Bard Mesh, there was an unreasonable risk of severe adverse reactions to the mesh or mesh components including: chronic pain; recurrence of hernia; foreign body response; rejection; infection; scarification; improper wound healing; excessive and chronic inflammation; allergic reaction; adhesions to internal organs; erosion; abscess; fistula formation; granulomatous response; seroma formation; nerve damage; tissue damage and/or death; and other complications.
- 37. Mesh porosity impacts tissue ingrowth and the inflammatory response. Large-pore meshes have fewer complications than small-pore meshes. A pore size greater than 1.5 mm defines "large-pore-size." Complications continue to decrease as mesh pore size increases

- beyond 1.5 mm. A small-pore-size decreases tissue incorporation, increases inflammation, and results in a fibrotic reaction. The Bard Mesh has a mesh pore size of less than 0.5 mm.
- 38. The polypropylene weave of the Bard Mesh produces very small interstices that allow bacteria to enter and hide from the host defenses designed to eliminate them. The bacteria can secrete an encasing slime (biofilm) that further serves to protect them from destruction by white blood cells and macrophages.
- 39. Observation of mesh under a scanning electron microscope reveals that very small interstices exists between the Bard Mesh fibrils, which are too small for a macrophage to enter to destroy incubating bacteria. Some bacteria are capable of degrading polypropylene.
- 40. These manufacturing and design defects associated with the Bard Mesh were directly and proximately related to the injuries Plaintiff suffered.
- 41. Neither Plaintiff nor Plaintiff's implanting physician was adequately warned or informed by Defendants of the defective and dangerous nature of Bard Mesh. Moreover, neither Plaintiff nor his implanting physician was adequately warned or informed by Defendants of the risks associated with the Bard Mesh.
- 42. The Bard Mesh implanted in Plaintiff failed to reasonably perform as intended. The Bard Mesh caused serious injury and had to be surgically removed via invasive surgery, and necessitated additional invasive surgery to repair the hernia that the Bard Mesh was initially implanted to treat.
- 43. As described above, there was an unreasonable risk that the Bard Mesh, which was defectively designed, would not perform safely and effectively for the purposes for which it was intended. Defendants failed to design against such dangers, and failed to provide adequate warnings and instructions concerning these risks.

- 44. Defendants expected and intended the Bard Mesh to reach users such as Plaintiff in the condition in which the Bard Mesh was sold.
- 45. The implantation of the Bard Mesh in Plaintiff's body was medically reasonable, and was a type of use that Defendants intended and foresaw when they designed, manufactured and sold the product.
- 46. The risks of the Bard Mesh significantly outweigh any benefits that Defendants contend could be associated with it.
- 47. The polypropylene mesh utilized to manufacture the Bard Mesh was in itself dangerous and defective, particularly when used in the manner intended by Defendants in the Bard Mesh. The particular polypropylene material used in the Bard Mesh was substandard, adulterated and non-medical grade, and was unreasonably subject to oxidative degradation within the body. When implanted as intended, adjacent internal organs, structures, nerves, arteries, and vessels, polypropylene mesh is unreasonably susceptible to adhesion formation, nerve entrapment, spermatic cord obliteration, organ perforation or erosion, fistula formation and bowel strangulation or hernia incarceration, and other injuries.
- 48. The appropriate treatment for complications associated with the Bard Mesh involves additional invasive surgery to remove the mesh from the body, thus eliminating any purported benefit that the mesh was intended to provide to a patient.
- 49. When the Bard Mesh was implanted in Plaintiff, there were safer feasible alternative designs for hernia mesh product, including but not limited to, a flat, non-coated, single layer, large pore mesh.

- 50. The Bard Mesh implanted in Plaintiff failed to reasonably perform as intended. It had to be surgically removed, necessitating further invasive surgery to repair the very issue that the product was intended to repair, and thus providing no benefit to Plaintiff.
- 51. As a direct and proximate result of the defective and unreasonably dangerous condition of the product, Plaintiff suffered injuries and damages as summarized in this Complaint.

COUNT III: STRICT LIABILITY – FAILURE TO WARN

- 52. Plaintiff incorporates by reference the allegations in all prior paragraphs.
- 53. When the Bard Mesh was implanted in Plaintiff's body, the warnings and instructions Defendants provided were inadequate and defective. As described above, there was an unreasonable risk that the product would not perform safely and effectively for the purposes for which it was intended, and Defendants failed to design and/or manufacture against such dangers, and failed to provide adequate warnings and instructions concerning these risks.
- 54. Defendants expected and intended the Bard Mesh product to reach users such as Plaintiff in the condition in which the product was sold.
- 55. Plaintiff and his physicians were unaware of the defects and dangers of the Bard Mesh, and were unaware of the frequency, severity and duration of the risks associated with the product.
- 56. The Instructions for Use for the Bard Mesh also failed to adequately warn Plaintiff's physicians of numerous risks that Defendants knew or should have known were associated with the Bard Mesh, including: risks of the product's immunologic response, pain, encapsulation, rejection, migration, scarification, contraction, adhesion to internal structures or

organs, erosion and migration through adjacent tissue and viscera, bowel obstruction, or hernia incarceration or strangulation.

- 57. Defendants failed as well to adequately warn Plaintiff or Plaintiff's physicians about the necessity for invasive surgical intervention in the event of complications with the Bard Mesh, or train the physicians on the proper treatment of such complications when they occurred.
- 58. Defendants failed to adequately warn Plaintiff or his physicians that: the surgical removal of the Bard Mesh in the event of complications would leave the hernia unrepaired; the resulting hernia would be much larger than the original; and further, more complicated medical treatment to attempt to repair the same hernia would be necessary.
- 59. With respect to the complications listed in their warnings, Defendants provided no information or warning regarding the frequency, severity and duration of those complications, although the complications associated with the Bard Mesh were more frequent, more severe and longer lasting than those in safer feasible alternative hernia repair treatments.
- 60. If Plaintiff and/or Plaintiff's physicians had been properly warned of the defects and dangers of the Bard Mesh, and of the frequency, severity and duration of the risks associated with the product, Plaintiff would not have consented to allow the Bard Mesh to be implanted, and Plaintiff's physicians would not have implanted the product in Plaintiff.
- 61. As a direct and proximate result of the inadequate and defective warnings and instructions, Plaintiff suffered injuries and damages as summarized in this Complaint.

COUNT IV: NEGLIGENCE

62. Plaintiff incorporates by reference the allegations in all prior Paragraphs.

- 63. Although Defendants had a duty to use reasonable care in designing, testing, inspecting, manufacturing, packaging, labeling, marketing, distributing, and preparing written instructions and warnings for the Bard Mesh, they failed to do so.
- 64. Defendants knew, or in the exercise of reasonable care should have known, that the Bard Mesh was defectively and unreasonably designed and/or manufactured, and were unreasonably dangerous and likely to injure patients in whom the product was implanted. Defendants knew or should have known that Plaintiff and Plaintiff's physicians were unaware of the dangers and defects inherent in the Bard Mesh.
- 65. Defendants knew or should have known that the Material Data Safety Sheet for the polypropylene used to manufacture their Bard Mesh prohibited permanently implanting the polypropylene into the human body.
 - 66. Defendants utilized non-medical grade polypropylene.
- 67. Defendants knew or should have known that polypropylene is not inert and would degrade, flake, chip, and disperse throughout the body once implanted.
- 68. Defendants knew or should have known that polypropylene incites a severe inflammatory response once implanted, and continues to incite a severe inflammatory response indefinitely or until removed.
- 69. Defendants knew or should have known that every piece of polypropylene that flakes off and migrates throughout the body also incites its own chronic inflammatory response wherever it embeds.
- 70. Defendants knew or should have known that small pore size of the Bard Mesh would increase mesh surface area which would increase the inflammatory and foreign body response.

71. As a direct and proximate result of Defendants' negligence in designing, testing, inspecting, manufacturing, packaging, labeling, marketing, distributing, and preparing written instructions and warnings for Bard Mesh, Plaintiff suffered injuries and damages as summarized in this Complaint.

COUNT V: BREACH OF EXPRESS WARRANTY

- 72. Plaintiff incorporates by reference the allegations in all prior paragraphs.
- 73. At all material times, Defendants manufactured, marketed, sold, distributed and otherwise placed in to the stream of commerce the Bard Mesh.
- 74. In advertising, marketing and otherwise promoting the Bard Mesh to physicians, hospitals and other healthcare providers, Defendants expressly warranted that their product was safe for use and reasonably fit for its intended purposes. In advertising, marketing and otherwise promoting the Bard Mesh, Defendants intended that physicians, hospitals and other healthcare providers rely upon their representations regarding safety and fitness, to induce them to implant the Bard Mesh in their patients.
- 75. With respect to Plaintiff, Defendants intended that the Bard Mesh be implanted by his treating surgeon in a reasonable and foreseeable manner, and in accordance with the instructions for use and product specifications provided by Defendants. Plaintiff was in privity with Defendants.
- 76. Defendants expressly warranted the following to physicians, hospitals, other healthcare providers and the general public, including Plaintiff: the Bard Mesh was safe and fit for use by consumers; it was of merchantable quality; its risks, side effects and potential complications were minimal and comparable to other hernia mesh product; it was adequately researched and tested; and it was fit for its intended use. Plaintiff and Plaintiff's physicians and

healthcare providers reasonably relied upon Defendants' express representations and warranties, and consequently, Plaintiff was implanted with Defendants' product.

- 77. Defendants expressly warranted to physicians, hospitals, other healthcare providers and the general public, including Plaintiff, that the Bard Mesh was safe and fit for use for the repair of hernias.
- 78. Defendants represented that the Bard Mesh would prevent or minimize hernia recurrence and pain, and facilitate incorporation of the mesh into the body, but it did not. Instead, the Bard Mesh caused an intense systemic inflammatory and chronic foreign body response, resulting in an adverse tissue reaction including damage to surrounding tissue in the form of sclerotic, granulomatous and/or fibrotic tissue and improper or delayed healing.
- 79. Defendants breached these express warranties because the Bard Mesh implanted in Plaintiff were unreasonably dangerous, defective, and not as Defendants had represented.
- 80. Defendants breached express representations and warranties to Plaintiff, as well as his physicians and healthcare providers, with respect to the Bard Mesh, by representing the following:
 - a. through labeling, advertising, marketing materials, detail persons, seminar presentations, publications, notice letters, and regulatory submissions, among other methods, that their product was safe; but they fraudulently withheld and concealed information about the substantial risks of serious injury associated with using the Bard Mesh.
 - b. the Bard Mesh was as safe and/or safer than other alternative procedures and devices on the market; but they fraudulently concealed information

- demonstrating that Bard Mesh was not safer than alternative therapies and product available on the market; and
- c. the Bard Mesh was more efficacious than other alternative procedures, therapies and/or devices; but they fraudulently concealed information regarding the true efficacy of the product.
- 81. Defendants' breach of their express warranties resulted in the implantation of unreasonably dangerous and defective product into Plaintiff, placing his health and safety in jeopardy.
- 82. When Defendants made such express warranties, they knew or should have known that their Bard Mesh did not conform to their express warranties. Defendants' acts were motivated by financial gain, while the adverse consequences of their conduct were outrageous, fraudulent, oppressive, done with malice or gross negligence and evidenced reckless indifference to Plaintiff's rights, health and safety, so as to warrant the imposition of punitive damages.

COUNT VI: VIOLATION OF FEDERAL & STATE CONSUMER PROTECTION LAWS

- 83. Plaintiff incorporates by reference the allegations in all prior paragraphs.
- 84. Plaintiff purchased and used the Bard Mesh primarily for personal use, and thereby suffered ascertainable losses as a result of Defendants' actions in violation of the consumer protection laws.
- 85. Had Defendants not engaged in the deceptive conduct described in this Complaint, Plaintiff would not have purchased and/or paid for the Bard Mesh, and would not have incurred related medical costs and injury.

- 86. Defendants engaged in wrongful conduct, while at the same time obtaining, under false pretenses, moneys from Plaintiff for the Bard Mesh, which would not have been paid had Defendants not engaged in unfair and deceptive conduct.
- 87. Unfair methods of competition or deceptive acts or practices that were proscribed by law, include the following:
 - a. representing that goods or services have characteristics, ingredients, uses,
 benefits or qualities that they do not have;
 - advertising goods or services with the intent not to sell them as advertised;
 and,
 - c. engaging in fraudulent or deceptive conduct that creates a likelihood of confusion or misunderstanding.
- 88. Plaintiff was injured by the cumulative and indivisible nature of Defendants' conduct. The cumulative effect of Defendants' conduct directed at patients, physicians and consumers was to create demand for and sell its Bard Mesh. Each aspect of Defendants' conduct combined to artificially create sales of the product.
- 89. Defendants have a statutory duty to refrain from unfair or deceptive acts or trade practices in the design, labeling, development, manufacture, promotion, and sale of the Bard Mesh.
- 90. Had Defendants not engaged in the deceptive conduct described above, Plaintiff would not have purchased and/or paid for the Bard Mesh, and would not have incurred related medical costs.
- 91. Defendants' deceptive, unconscionable, or fraudulent representations and material omissions to patients, physicians and consumers, including Plaintiff, constituted unfair and

deceptive acts and trade practices in violation of the federal and state consumer protection statutes listed below.

- 92. Defendants' actions constitute unfair competition or unfair, unconscionable, deceptive or fraudulent acts, or trade practices in violation of federal and state consumer protection statutes listed below.
- 93. Defendants have engaged in unfair competition or unfair or deceptive acts or trade practices or false advertising, or have made false representations in violation of:
 - a. 15 U.S.C. §§ 2301-2312 (1982)
 - b. 73 P.S. §§ 201-1 –201-9.2, et. seq.
 - c. N.J. Stat. Ann §§ 56:8-1, et. seq.
 - d. R.I. Gen. Laws §§ 6-13.1, et. seq.
- 94. Under the statutes listed above Defendants are the suppliers, manufacturers, advertisers, and sellers subject to liability under such legislation for unfair, deceptive, fraudulent and unconscionable consumer sales practices.
- 95. Defendants violated the statutes enacted in these states to protect consumers against unfair, deceptive, fraudulent and unconscionable trade and business practices and false advertising, by knowingly and falsely representing that its Bard Mesh was fit to be used for the purpose for which they were intended, when in fact they were defective and dangerous, and by other acts alleged in this Complaint. These representations were made in marketing and promotional materials.
- 96. Defendants' actions and omissions are uncured or incurable deceptive acts under the consumer protection laws.

- 97. Defendants had actual knowledge of the defective and dangerous condition of its Bard Mesh and failed to take any action to cure such defective and dangerous conditions.
- 98. Plaintiff and the medical community relied upon Defendants' misrepresentations and omissions in determining which product and/or procedure to undergo and/or perform (if any).
- 99. Defendants' deceptive, unconscionable or fraudulent representations and material omissions to patients, physicians and consumers, constituted unfair and deceptive acts and practices.
- 100. By reason of the unlawful acts in which Defendants engaged, and as a direct and proximate result of those acts, Plaintiff has suffered ascertainable losses and damages.
- 101. As a direct and proximate result of Defendants' violations of the consumer protection laws, Plaintiff has sustained economic losses and other damages and is entitled to statutory and compensatory damages in an amount to be proven at trial.

COUNT VII: NEGLIGENT INFLICTION OF EMOTIONAL DISTRESS

- 102. Plaintiff incorporates by reference the allegations in all prior paragraphs.
- 103. Defendants carelessly and negligently manufactured, designed, developed, tested, labeled, marketed and sold the Bard Mesh to Plaintiff.
- 104. Defendants carelessly and negligently concealed the harmful effects of their product from Plaintiff, individually and/or Plaintiff's physician, on multiple occasions. They continue to do so to this day.
- 105. Defendants carelessly and negligently misrepresented the quality, safety and efficacy of the Bard Mesh to Plaintiff, individually and/or Plaintiff's physician, on multiple occasions. They continue to do so to this day.

- 106. Plaintiff was directly impacted by Defendants' carelessness and negligence, in that he has sustained and will continue to sustain emotional distress, severe physical injuries, economic losses, and other damages as a direct result of the decision to purchase the Bard Mesh sold and distributed by Defendants.
- 107. Defendants continued to carelessly and negligently misrepresent the quality, safety, efficacy, dangers and contraindications of the Bard Mesh to Plaintiff, individually and/or Plaintiff's physician, after Plaintiff sustained emotional distress, severe physical injuries, and economic loss.
- 108. Defendants continued to carelessly and negligently misrepresent the quality, safety, efficacy, dangers and contraindications of the Bard Mesh to Plaintiff, individually and/or Plaintiff's physician, knowing that doing so would cause his to suffer additional and continued emotional distress, severe physical injuries, and economic loss.
- 109. As a proximate result of the Defendants' acts or omissions, Plaintiff has been injured, sustained severe and permanent pain, suffering, anxiety, depression, disability, impairment, loss of enjoyment of life, loss of care, comfort, and economic damages.

COUNT VIII: FRAUDULENT CONCEALMENT

- 110. Plaintiff incorporates by reference the allegations in all prior paragraphs.
- 111. At all material times, Defendants knew or should have known that the Bard Mesh caused large numbers of complications. Moreover, they also knew or should have known the following: the surgical technique and training of implanting physicians was not the cause of the adverse events associated with these devices; the safety and efficacy of its Bard Mesh had not been proven with respect to, among other things, the product, its components, its performance,

and its method of insertion; the Bard Mesh was not safe and effective. But Defendants continued to represent that the Bard Mesh was safe and effective.

- 112. Despite what Defendants knew or should have known about the lack of safety and efficacy of the Bard Mesh, they failed to disclose this information to Plaintiff, to Plaintiff's physicians, and to the public at large.
- 113. At all material times, Defendants had the duty and obligation to disclose to Plaintiff and Plaintiff's physicians the true facts concerning the Bard Mesh: that they were dangerous and defective, lacking efficacy for their purported use and lacking safety in normal use, and the likelihood of them causing serious consequences to users, including permanent and debilitating injuries. Defendants concealed these material facts before Plaintiff was implanted with their product.
- 114. Defendants were under a duty to Plaintiff to disclose and warn of the defective nature of the Bard Mesh because:
 - a. Defendants were in a superior position to know the true quality, safety, and efficacy of the Bard Mesh;
 - b. Defendants knowingly made false claims in documents and marketing materials about the safety and quality of the Bard Mesh; and
 - Defendants fraudulently and affirmatively concealed the defective nature of the Bard Mesh from Plaintiff.
- 115. The facts concealed and/or not disclosed by Defendants to Plaintiff and his physician were material facts that a reasonable person would have considered to be important in deciding whether to purchase and/or use the Bard Mesh.

- 116. At all material times, Defendants willfully, intentionally, and maliciously concealed facts as set forth above from Plaintiff and his physician, with the intent to defraud.
- 117. Defendants intentionally concealed and/or failed to disclose the true defective nature of the Bard Mesh so that Plaintiff would request and purchase the product, and his healthcare providers would dispense, prescribe, and recommend the Bard Mesh; and Plaintiff justifiably acted or relied upon the concealed and/or non-disclosed facts to his detriment.
- 118. At all material times, neither Plaintiff nor Plaintiff's physician was aware of the facts set forth above. Had they been aware of the facts, they would not have acted as they did, i.e., would not reasonably relied upon the representations of safety and efficacy and utilized the Bard Mesh in their treatment. Defendants' failure to disclose this information was a substantial factor in Plaintiff's physicians selecting Defendants' Bard Mesh. The failure to disclose also resulted in the provision of incorrect and incomplete information to Plaintiff, as a patient.
 - 119. As a direct and proximate result of Defendants' conduct, Plaintiff was injured.

COUNT IX: NEGLIGENT MISREPRESENTATION

- 120. Plaintiff incorporates by reference the allegations in all prior paragraphs.
- 121. Defendants had a duty to accurately and truthfully represent to the medical and healthcare community, Plaintiff, and the public, that the Bard Mesh had not been adequately tested and found to be a safe and effective treatment. Defendants' representations were in fact false.
- 122. Defendants failed to exercise ordinary care in the representations concerning the Bard Mesh while they were involved in its manufacture, sale, testing, quality assurance, quality control, and distribution in interstate commerce, because Defendants negligently misrepresented or concealed the Bard Mesh' high risk of unreasonable and dangerous adverse side effects.

- 123. Defendants breached their duty in representing to Plaintiff, Plaintiff's physicians, and the medical community, that the Bard Mesh had no serious side effects different from those of other similar product and/or procedures.
- 124. As a foreseeable, direct, and proximate result of Defendants' negligent misrepresentation, they knew or should have known that the Bard Mesh had been insufficiently tested, or had not been tested at all. As well, they knew or should have known that the product lacked adequate and accurate warnings, creating a high risk—or higher than acceptable or reported and represented risk—of adverse side effects. Those included pain, graft rejection, graft migration, organ damage, complex seroma, fistula, sinus tract formation, delayed wound closure, infection, sepsis, and death.
- 125. As a direct and proximate result of Defendants' acts and omissions, Plaintiff has been injured and sustained severe pain, suffering, disability, impairment, loss of enjoyment of life, loss of care, comfort, economic damages.

PUNITIVE DAMAGES

- 126. Plaintiff incorporates the allegations in all prior paragraphs.
- 127. Defendants failed to adequately test and study the Bard Mesh to determine and ensure that the product was safe and effective before releasing the product for sale for permanent human implantation; and Defendants continued to manufacture and sell the product after having obtained knowledge and information that they were defective and unreasonably unsafe.
- 128. At all material times, Defendants knew or should have known that the Bard Mesh was inherently more dangerous with respect to the following risks: migration, foreign body response, allergic reactions, rejection, infection, failure, erosion, pain and suffering, organ perforation, dense adhesions, loss of life's enjoyment, remedial surgeries and treatments in an

effort to cure the conditions proximately related to the product's use, as well as other permanent and lasting severe and personal injuries.

- 129. Defendants' misrepresentations included knowingly withholding material information from the medical community and the public, including Plaintiff, concerning the safety and efficacy of the Bard Mesh, thus depriving Plaintiff and his implanting physicians of vitally necessary information necessary to make a fully informed decision about whether to use the product.
- 130. At all material times, Defendants knew and recklessly and/or intentionally disregarded the fact that the Bard Mesh can cause debilitating and potentially life-threatening side effects with greater frequency than safer alternative methods, product, procedures, and/or treatment. But they recklessly failed to advise the medical community and the general public, including Plaintiff, of the risks and side effects.
- 131. At all material times, Defendants intentionally misstated and misrepresented data, and continue to misrepresent data, so as to minimize the perceived risk of injuries and the rate of complications associated with Bard Mesh.
- 132. Notwithstanding the foregoing and the growing body of knowledge and information regarding the true and defective nature of the Bard Mesh' increased risk of side effects and serious complications, Defendants continue to aggressively market the product to the medical community and to consumers without disclosing the true risk of such complications.
- 133. When Plaintiff was implanted with the Bard Mesh and since then, Defendants have known that the Bard Mesh was defective and unreasonably dangerous. Nonetheless, they have continued to manufacture, produce, assemble, market, distribute, and sell the product so as to maximize sales and profits at the expense of the health and safety of the public, in a conscious

reckless and/or intentional disregard of the likely and foreseeable harm caused by the Bard Mesh to the public, including Plaintiff.

- 134. At all material times, Defendants have concealed and/or failed to disclose to the public the serious risks and the potential complications associated with the Bard Mesh, to ensure continued and increased sales and profits, to the detriment of the public, including Plaintiff.
- 135. Defendants' acts and omissions are of such character and nature so as to entitle Plaintiff to an award of punitive damages in accordance with applicable statutory and common law. Defendants' conduct shows willful misconduct, malice, fraud, wantonness, oppression, or that entire want of care, which raise the presumption of conscious indifference to consequences, thereby justifying an award of punitive damages.

WHEREFORE, Plaintiff demands judgment against Defendants, individually, jointly, and severally; and requests compensatory damages, punitive damages or enhanced compensatory damages, together with interest, costs of suit, attorneys' fees, and such further relief as the Court deems equitable and just.

PRAYER FOR RELIEF

Plaintiff demands judgment against Defendants, individually, jointly and severally, and prays for the following relief in accordance with applicable law and equity:

- I. Compensatory damages to Plaintiff for past, present, and future damages, including but not limited to, pain and suffering for severe and permanent personal injuries sustained by Plaintiff, permanent impairment, mental pain and suffering, loss of enjoyment of life, health and medical care costs, economic damages, together with interest and costs as provided by law;
- II. restitution and disgorgement of profits;

- III. punitive or enhanced compensatory damages;
- IV. reasonable attorneys' fees as provided by law;
- V. costs of these proceedings, including past and future costs of suit;
- VI. all ascertainable economic damages;
- VII. prejudgment interest on all damages as allowed by law; and
- VIII. such other and further relief as this Court deems just and proper.

DEMAND FOR JURY TRIAL

Plaintiff Stanley Pliszka hereby demands a trial by jury on all issues so triable.

Respectfully submitted,

By: /s/ Morris Dweck

Morris Dweck

BERNSTEIN LIEBHARD LLP

10 East 40th Street

New York, New York 10016

Tel: (212) 779-1414

Fax: (212) 779-3218

Email: mdweck@bernlieb.com

Attorneys for Plaintiff

Dated: June 28, 2018

JS 44 (Rev. 08/16)

Case 2:18-cv-12325 Decline to VERSHEE 18 Page 1 of 2 PageID: 26

The JS 44 civil cover sheet and the information contained herein neither replace nor supplement the filing and service of pleadings or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. (SEE INSTRUCTIONS ON NEXT PAGE OF THIS FORM.)

purpose of initiating the civil do	ocket sheet. (ŜĒE INSTRŪC	TIONS ON NEXT PAGE OF	F THIS FO	RM.)	•					
I. (a) PLAINTIFFS Stanley Pliszka				DEFENDANTS C.R.BARD. INC., AND BARD DAVOL, INC						
(b) County of Residence of First Listed Plaintiff Philidelphia, PA (EXCEPT IN U.S. PLAINTIFF CASES) (c) Attorneys (Firm Name, Address, and Telephone Number) Bernstein Liebhard LLP, 10 E. 40th Street, New York, NY 10016. (212) 7				County of Residence of First Listed Defendant Union County (IN U.S. PLAINTIFF CASES ONLY) NOTE: IN LAND CONDEMNATION CASES, USE THE LOCATION OF THE TRACT OF LAND INVOLVED. Attorneys (If Known)						
II. BASIS OF JURISD	ICTION (Place an "X" in	One Box Only)	III. CIT	TIZENSHIP OF PR	RINCIPA	L PARTIES	Place an "X" in C	One Box for	Plaintiff	
☐ 1 U.S. Government Plaintiff	☐ 3 Federal Question (U.S. Government Not a Party)		(.	For Diversity Cases Only) PT n of This State	TF DEF	Incorporated or Pri	and One Box			
2 U.S. Government Defendant			Citize	Citizen of Another State 2 2 Incorporated and Principal Place of Business In Another State				□ 5	□5	
				Citizen or Subject of a 3 5 Foreign Nation 6 Foreign Country						
IV. NATURE OF SUIT		•				for: Nature of S		_		
CONTRACT 110 Insurance 120 Marine 130 Miller Act 140 Negotiable Instrument 150 Recovery of Overpayment & Enforcement of Judgment 151 Medicare Act 152 Recovery of Defaulted Student Loans (Excludes Veterans) 153 Recovery of Overpayment of Veteran's Benefits 160 Stockholders' Suits 190 Other Contract 195 Contract Product Liability 196 Franchise REAL PROPERTY 210 Land Condemnation 220 Foreclosure 230 Rent Lease & Ejectment 240 Torts to Land 245 Tort Product Liability 290 All Other Real Property	PERSONAL INJURY 310 Airplane 315 Airplane Product Liability 320 Assault, Libel & Slander 330 Federal Employers' Liability 340 Marine 345 Marine Product Liability 350 Motor Vehicle Product Liability 360 Other Personal Injury 362 Personal Injury Medical Malpractice CIVIL RIGHTS 440 Other Civil Rights 441 Voting 441 Voting 443 Housing/ Accommodations 445 Amer. w/Disabilities - Employment 446 Amer. w/Disabilities - Other 448 Education	PERSONAL INJURY 365 Personal Injury - Product Liability 367 Health Care/ Pharmaceutical Personal Injury Product Liability 368 Asbestos Personal Injury Product Liability PERSONAL PROPER' 370 Other Fraud 371 Truth in Lending 380 Other Personal Property Damage 385 Property Damage 385 Property Damage Product Liability PRISONER PETITION Habeas Corpus: 463 Alien Detainee 510 Motions to Vacate Sentence 530 General 535 Death Penalty Other: 540 Mandamus & Othe 550 Civil Rights 555 Prison Condition 560 Civil Detainee - Conditions of	TY	EXPETITURE/PENALTY To Drug Related Seizure To Property 21 USC 881 To Other LABOR The Pair Labor Standards Act The Pair Labor Standards Act The Pair Labor Act The Pa	422 Appe	RTY RIGHTS rrights at emark SECURITY (1395ff) k Lung (923) C/DIWW (405(g)) Title XVI	375 False C 376 Qui Ta 3729(a 400 State R 410 Antitru 430 Banks : 450 Comme 460 Deport: 470 Racket 470 Racket 200 Corrupt 480 Consur 490 Cable/S 850 Securit Exchat 890 Other S 891 Agricul 893 Envirot 895 Freedo: Act 896 Arbitra 899 Admin Act/Rev	m (31 USC))) eapportion st and Bankin erce ation eer Influen to Organizat ner Credit Sat TV ies/Commo nge Statutory A ltural Acts tural Acts t	nment ng nced and tions odities/ actions latters mation rocedure	
	moved from 3 te Court	Appellate Court	4 Reins Reope	<u> </u>	District	6 Multidistri Litigation Transfer		Multidist Litigatio Direct F	n -	
VI. CAUSE OF ACTIO	28 USC Section 1332	use:	c ming (D	о пос сис запъшенопи Stati	шез ишез и	rerousy).				
VII. REQUESTED IN COMPLAINT:		IS A CLASS ACTION	DI	EMAND \$		CHECK YES only:		complair	nt:	
VIII. RELATED CASI IF ANY	E(S) (See instructions):	JUDGE			DOCKE	T NUMBER				
DATE 08/01/2018		SIGNATURE OF ATT								

JS 44 Reverse (Rev. 08/16)

INSTRUCTIONS FOR ATTORNEYS COMPLETING CIVIL COVER SHEET FORM JS 44

Authority For Civil Cover Sheet

The JS 44 civil cover sheet and the information contained herein neither replaces nor supplements the filings and service of pleading or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. Consequently, a civil cover sheet is submitted to the Clerk of Court for each civil complaint filed. The attorney filing a case should complete the form as follows:

- **I.(a)** Plaintiffs-Defendants. Enter names (last, first, middle initial) of plaintiff and defendant. If the plaintiff or defendant is a government agency, use
- (b) County of Residence. For each civil case filed, except U.S. plaintiff cases, enter the name of the county where the first listed plaintiff resides at the
- (c) Attorneys. Enter the firm name, address, telephone number, and attorney of record. If there are several attorneys, list them on an attachment, noting in this section "(see attachment)".
- II. Jurisdiction. The basis of jurisdiction is set forth under Rule 8(a), F.R.Cv.P., which requires that jurisdictions be shown in pleadings. Place an "X" United States plaintiff. (1) Jurisdiction based on 28 U.S.C. 1345 and 1348. Suits by agencies and officers of the United States are included here. United States defendant. (2) When the plaintiff is suing the United States, its officers or agencies, place an "X" in this box. Federal question. (3) This refers to suits under 28 U.S.C. 1331, where jurisdiction arises under the Constitution of the United States, an amendment Diversity of citizenship. (4) This refers to suits under 28 U.S.C. 1332, where parties are citizens of different states. When Box 4 is checked, the citizenship of the different parties must be checked. (See Section III below; NOTE: federal question actions take precedence over diversity cases.)
- **III. Residence (citizenship) of Principal Parties.** This section of the JS 44 is to be completed if diversity of citizenship was indicated above. Mark this section for each principal party.
- **IV. Nature of Suit.** Place an "X" in the appropriate box. If there are multiple nature of suit codes associated with the case, pick the nature of suit code that is most applicable. Click here for: <u>Nature of Suit Code Descriptions</u>.
- **V. Origin.** Place an "X" in one of the seven boxes.
 - Original Proceedings. (1) Cases which originate in the United States district courts.
 - Removed from State Court. (2) Proceedings initiated in state courts may be removed to the district courts under Title 28 U.S.C., Section 1441. Remanded from Appellate Court. (3) Check this box for cases remanded to the district court for further action. Use the date of remand as the filing Reinstated or Reopened. (4) Check this box for cases reinstated or reopened in the district court. Use the reopening date as the filing date. Transferred from Another District. (5) For cases transferred under Title 28 U.S.C. Section 1404(a). Do not use this for within district transfers or multidistrict litigation transfers.
 - Multidistrict Litigation Transfer. (6) Check this box when a multidistrict case is transferred into the district under authority of Title 28 U.S.C. Multidistrict Litigation Direct File. (8) Check this box when a multidistrict case is filed in the same district as the Master MDL docket. **PLEASE NOTE THAT THERE IS NOT AN ORIGIN CODE 7.** Origin Code 7 was used for historical records and is no longer relevant due to changes in statue.
- VI. Cause of Action. Report the civil statute directly related to the cause of action and give a brief description of the cause. Do not cite jurisdictional statutes unless diversity. Example: U.S. Civil Statute: 47 USC 553 Brief Description: Unauthorized reception of cable service
- VII. Requested in Complaint. Class Action. Place an "X" in this box if you are filing a class action under Rule 23, F.R.Cv.P.

 Demand. In this space enter the actual dollar amount being demanded or indicate other demand, such as a preliminary injunction.

 Jury Demand. Check the appropriate box to indicate whether or not a jury is being demanded.
- **VIII. Related Cases.** This section of the JS 44 is used to reference related pending cases, if any. If there are related pending cases, insert the docket numbers and the corresponding judge names for such cases.

Date and Attorney Signature. Date and sign the civil cover sheet.